{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:58:43Z","timestamp":1760367523374},"reference-count":55,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:p>Eriksson C, Rantap\u00e4\u00e4\u2010Dahlqvist S, Sundqvist K\u2010G. T\u2010cell expression of CD91 \u2013 a marker of unresponsiveness to anti\u2010TNF therapy in rheumatoid arthritis. APMIS 2010; 118: 837\u201345.<\/jats:p><jats:p>The aim of this study was to investigate the expression of thrombospondin\u20101 (TSP\u20101) and its receptors, lipoprotein receptor\u2010related protein\/cluster of differentiation (CD)91, calreticulin (CRT), and CD47, on T cells and monocytes from patients with rheumatoid arthritis (RA) treated with anti\u2010tumor necrosis factor (TNF) therapy. The surface expression of CD91 and associated components on CD3\u2010 and CD14\u2010positive cells was examined using flow cytometry in 12 patients with established RA before and after beginning therapy and compared with that of 9 healthy controls and 12 patients with early RA treated with conventional therapies. CD3\u2010positive cells from anti\u2010TNF non\u2010responders showed significantly greater expression of CD91 expression than those from responders (p\u2003&lt;\u20030.05) after 6\u2003weeks and when all measurements were pooled (p\u2003&lt;\u20030.001). CD91 expression on CD3\u2010positive cells from non\u2010responders to other therapies was at the same level as in healthy controls. In contrast, CD14\u2010positive cells showed no differences in CD91 expression between patients and controls or between responders and non\u2010responders to anti\u2010TNF therapy. The expression of TSP\u20101, CRT, and CD47 showed no differences between responders and non\u2010responders. The results suggest T\u2010lymphocyte expression of CD91 to be a biomarker that signifies unresponsiveness to anti\u2010TNF therapy in patients with RA and may be used to identify potential responders and non\u2010responders.<\/jats:p>","DOI":"10.1111\/j.1600-0463.2010.02677.x","type":"journal-article","created":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T18:09:28Z","timestamp":1283537368000},"page":"837-845","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["T\u2010cell expression of CD91 \u2013 a marker of unresponsiveness to anti\u2010TNF therapy in rheumatoid arthritis"],"prefix":"10.1111","volume":"118","author":[{"given":"CATHARINA","family":"ERIKSSON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SOLBRITT","family":"RANTAP\u00c4\u00c4\u2010DAHLQVIST","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KARL\u2010G\u00d6STA","family":"SUNDQVIST","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400403"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011565"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2832"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/422827"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.09.011"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1868"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2214"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/516736"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22703"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32805e87e0"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.06.002"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00637.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113992"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01371.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016832"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200204)32:4<1069::AID-IMMU1069>3.0.CO;2-E"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.654"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-006-6255-8"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020634924760"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8924(00)01906-1"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5930"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302014200"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202200200"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200109098"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.09.017"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.9.6359"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.6994"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.12.004"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0105049"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.6.3582"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0620"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2010.04.007"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080440"},{"key":"e_1_2_7_39_2","first-page":"529","article-title":"Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis","volume":"24","author":"Klimiuk PA","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.07.002"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024182"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1173"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9214-3"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080626"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00073-4"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/385729a0"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.1272"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.163"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804336"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00049-2"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mn.7800196"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.107649"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/77835"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00111-X"},{"key":"e_1_2_7_55_2","first-page":"16","article-title":"Naturally formed or artificially reconstituted non\u2010covalent alpha2\u2010macroglobulin\u2010peptide complexes elicit CD91\u2010dependent cellular immunity","volume":"2","author":"Binder RJ","year":"2002","journal-title":"Cancer Immun"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.12.004"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0463.2010.02677.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0463.2010.02677.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T04:40:41Z","timestamp":1698727241000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0463.2010.02677.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,2]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1600-0463.2010.02677.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0463.2010.02677.x","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,2]]},"assertion":[{"value":"2010-09-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}